Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence

BACKGROUND: Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B indicated to prevent C. difficile infection (CDI) recurrence (rCDI) in adults at high risk for rCDI. This post hoc analysis of pooled monocolonal antibodies for C.difficile therapy (MODIFY) I/II data assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerding, Dale N, Kelly, Ciaran P, Rahav, Galia, Lee, Christine, Dubberke, Erik R, Kumar, Princy N, Yacyshyn, Bruce, Kao, Dina, Eves, Karen, Ellison, Misoo C, Hanson, Mary E, Guris, Dalya, Dorr, Mary Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093994/
https://www.ncbi.nlm.nih.gov/pubmed/29538686
http://dx.doi.org/10.1093/cid/ciy171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093994/
https://www.ncbi.nlm.nih.gov/pubmed/29538686
http://dx.doi.org/10.1093/cid/ciy171

Ejemplares similares